SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia
Open Access
- 14 December 2017
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 130 (24) , 2631-2641
Abstract
Mutations in SETD2, encoding the histone 3 lysine 36 trimethyltransferase, are enriched in relapsed acute lymphoblastic leukemia and MLL-rearranged acute leukemia. We investigated the impact of SETD2 mutations on chemotherapy sensitivity in isogenic leukemia cell lines and in murine leukemia generated from a conditional knockout of Setd2. SETD2 mutations led to resistance to DNA-damaging agents, cytarabine, 6-thioguanine, doxorubicin, and etoposide, but not to a non–DNA damaging agent, l-asparaginase. H3K36me3 localizes components of the DNA damage response (DDR) pathway and SETD2 mutation impaired DDR, blunting apoptosis induced by cytotoxic chemotherapy. Consistent with local recruitment of DDR, genomic regions with higher H3K36me3 had a lower mutation rate, which was increased with SETD2 mutation. Heterozygous conditional inactivation of Setd2 in a murine model decreased the latency of MLL-AF9–induced leukemia and caused resistance to cytarabine treatment in vivo, whereas homozygous loss delayed leukemia formation. Treatment with JIB-04, an inhibitor of the H3K9/36me3 demethylase KDM4A, restored H3K36me3 levels and sensitivity to cytarabine. These findings establish SETD2 alteration as a mechanism of resistance to DNA-damaging chemotherapy, consistent with a local loss of DDR, and identify a potential therapeutic strategy to target SETD2-mutant leukemias. Publisher9s Note: There is an Inside Blood Commentary on this article in this issue. Key Points Alterations of SETD2, a histone 3 lysine 36 trimethyl (H3K36me3) transferase leads to resistance to DNA damaging-chemotherapy in leukemia. Low H3K36me3 levels impair DNA damage response and increase mutation rate, which may be targeted by H3K36me3 demethylase inhibition. Visual AbstractKeywords
This publication has 47 references indexed in Scilit:
- Prognostic Value of SETD2 Expression in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase InhibitorsJournal of Urology, 2016
- Genomic complexity and dynamics of clonal evolution in childhood acute myeloid leukemia studied with whole-exome sequencingOncotarget, 2016
- Exploring genomic alteration in pediatric cancer using ProteinPaintNature Genetics, 2015
- Decreased Expression of SETD2 Predicts Unfavorable Prognosis in Patients With Nonmetastatic Clear-Cell Renal Cell CarcinomaMedicine, 2015
- Quantitative ChIP-Seq Normalization Reveals Global Modulation of the EpigenomeCell Reports, 2014
- Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editingNature Biotechnology, 2014
- SETD2 is required for DNA double-strand break repair and activation of the p53-mediated checkpointeLife, 2014
- Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemiaNature Communications, 2014
- Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9Nature, 2006
- Identification and Characterization of a Novel Human Histone H3 Lysine 36-specific MethyltransferaseJournal of Biological Chemistry, 2005